Skip to main content
. Author manuscript; available in PMC: 2012 Dec 1.
Published in final edited form as: Arthritis Rheum. 2011 Dec;63(12):3649–3660. doi: 10.1002/art.30605

Table 4. Performance on three rheumatoid arthritis (RA) quality measures (QMs).

RA QMs Population Findings
DMARD use in RA

  • Claims data

  • Medical record review
RA treatment
acceleration*

  • Medical record review

  • 46% with moderate disease activity had treatment acceleration (42)

  • 80% with severe disease activity had treatment acceleration (42)

  • 85% RA treatment acceleration (44)

  • 50-64% treatment acceleration (43)
RA core data set**

  • Medical record review

  • 69% RA core data set (44)

  • Joint exam: 98%, functional status: 83%, global assessment: 91%, ESR or CRP: 66%, pain: 92% (43)
*

See Table 2.

**

RA core data set = IF a patient has a diagnosis of RA, THEN each of the following should be documented within 3 months of diagnosis and at appropriate time intervals thereafter: a joint exam, functional status, disease activity (presence/ absence of synovitis, ESR/ CRP) and pain (20)